Built for Anti-Infective Research
From the first in vitro susceptibility screens to full in vivo efficacy data packages, TransPharm Preclinical Solutions covers the complete preclinical workflow for anti-infective drug development.
Murine and rat models for pneumonia, sepsis, thigh, UTI, wound, osteomyelitis, and more. PK/PD and maximum tolerated dose studies also available.
MIC, MBC, time-kill kinetics, checkerboard analyses, and more—performed against our validated pathogen library using CLSI-standard methods.
Hundreds of validated strains—including multidrug-resistant isolates—available on-site. Additional strains sourced on request.
Study reports, regulatory summaries, and manuscript preparation by scientists who ran the work. Clear, defensible, submission-ready.
A Complete Workflow
From the First Susceptibility Test to the Final Report
Many clients move through our services in sequence—establishing in vitro activity, advancing the most promising candidates into in vivo efficacy models, then leaving with a defensible, submission-ready data package. Others come to us for a single, specific study. Either way, the work is customized to your program.
Establish baseline potency against target and resistant strains.
Advance lead candidates into validated infection models — the heart of what we do.
Receive clear, regulatory-ready documentation of your results.
Additional Services
Everything a Complete Study Needs
Beyond our core testing, we provide the supporting services that round out a program — some run in-house, others coordinated and managed by TransPharm Preclinical Solutions through trusted partner labs, so you always have a single point of contact.
Exposure-response, dose fractionation, and single- and multiple-dose pharmacokinetics that guide dosing.
New in vivo infection models designed and validated around your compound and endpoints.
Precise tissue collection to support burden, histology, bioanalysis, and PK/PD endpoints.
Tissue processing, staining, and pathology, managed by TransPharm Preclinical Solutions through partner labs.
LC-MS/MS quantification of drug levels in blood and tissue to power PK/PD endpoints.
Study reports, regulatory summaries, and manuscripts authored by the scientists who ran the work.